MedTrace Logo

Dietary Supplementation on Tear Secretion and Inflammation in DES

NCT06738446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-05-14

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the effect of supplementation of fish oil, lutein and zeaxanthin on the symptoms of dry eye syndrome, antioxidant capacity, oxidative stress and anti-inflammatory capacity in DES patients., it aims to answer are:

To evaluate the effects of a 12-week multicomponent dietary supplementation (capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg)on symptoms of dry eye syndrome, oxidative stress, antioxidant capacity, and inflammation.

To investigate the relationships between dry eye symptoms, oxidative stress, antioxidant capacity, and inflammation.

Participants will be randomly assigned to control group (n = 50) and supplement group (n = 50) and white pomegranate extract group (n = 50) for 12 weeks. Participants will complete assessments of tear secretion, antioxidant capacity, and ocular surface inflammation.

Conditions

  • Dry Eye Syndrome (DES)

Interventions

DIETARY_SUPPLEMENT

Multicomponent dietary supplement group

Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks

Sponsors & Collaborators

  • Far East Bio-Tec Co., Ltd

    collaborator INDUSTRY

  • Shih Chien Huang

    lead OTHER

Principal Investigators

  • Shih-Chien Huang, Dr · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2022-04-02
Completion
2022-06-14

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738446 on ClinicalTrials.gov